The Latest Breaking News from Joe Wolk

Johnson & Johnson Credits Tariff Delays For Strong Earnings, While Jim Cramer Pegs It On 'Lower Than Thought' Levies

Johnson Johnson (NYSE:JNJ) delivered better-than-expected second quarter results, with the management hinting at leveraging tariff delays to maintain its outlook; however, CNBC’s Jim Cramer credited the performance to lower tariffs.

Benzinga · Jul 17, 2025

Johnson & Johnson Lifts Annual Forecast After Strong Cancer Drugs, Medtech Performance

Johnson Johnson (NYSE:JNJ) on Wednesday reported a second-quarter 2025 adjusted earnings of $2.77 per share, down 1.8% year over year, beating the consensus of $2.68.

Benzinga · Jul 16, 2025

J&J CEO Slams Biden's Drug Pricing Law, Says It Will 'Chill' Innovation

J&J CEO explained that the new drug-price negotiation law threatens development of new drugs, according to Bloomberg.

International Business Times · Sep 12, 2024